Denis Poddubnyy, ACR 2021: Secukinumab and HLA Subtypes in AxSpA
Prof. Denis Poddubny (Charité-Universitätsmedizin Berlin, Berlin, Germany) kindly took the time to speak with touchIMMUNOLOGY about the post-hoc analysis from the phase 3b SKIPPAIN trial (NCT03136861) aimed at exploring the potential association of HLA-B27 subtypes on the effect of secukinumab in patients with axSpA.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
His presentation entitled ‘Efficacy of Secukinumab and HLA-B27 Subtypes: Results from a Phase IIIb Randomised Controlled Trial in Axial SpA’ (ABSTRACT NUMBER: 0917) was presented at the ACR Convergence, 5-9 November 2021.
- What is known about the association between human leukocyte antigen (HLA) subtypes and axial spondyloarthritis? (0:12)
- What were the aims and methodology of this post hoc analysis of the SKIPPAIN trial data? (1:15)
- What were the findings of the analysis? (1:40)
- What questions remain unanswered about HLA-B27 subtypes and what future studies are planned? (2:17)
Disclosures: Prof. Denis Poddubnyy has received research support from AbbVie, Eli Lilly, MSD, Novartis, and Pfizer; consulting fees from AbbVie, Biocad, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, Samsung Bioepis, and UCB; and speaker fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
Share this Video
Related Videos In Axial Spondyloarthritis
Xenofon Baraliakos, ACR 2022: Bimekizumab in the treatment of active non-radiographic axial spondyloarthritis and ankylosing spondylitis – 52 week findings from BE MOBILE 1 and 2
Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits both IL-17F and IL‑17A, was recently investigated in the phase 3 BE MOBILE 1 (NCT03928704) and BE MOBILE 2 (NCT03928743) clinical trials for active non-radiographic axial spondyloarthritis and ankylosing spondylitis, respectively. touchIMMUNOLOGY were delighted to speak with Dr. Xenofon Baraliakos (Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany) to discuss […]
Sofia Ramiro, ACR 2022: Ixekizumab for radiographic axial spondyloarthritis – findings from the COAST-V trial
The COAST-V trial (NCT02696785) investigated the efficacy and safety of ixekizumab in patients with radiographic axial spondyloarthritis who were biological disease-modifying anti-rheumatic drug naïve. It was a pleasure to talk with Dr. Sofia Ramiro (Leiden University Medical Center, Leiden, Netherlands) to discuss the findings in terms of patient reported outcomes at weeks 16 and 52 […]
Xenofon Baraliakos, EULAR 2022: Bimekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis – BE MOBILE 1
BE MOBILE 1 (ClinicalTrials.gov Identifier: NCT03928704) is a a phase 3 study investigating bimekizumab in the treatment of active non-radiographic axial spondyloarthritis. touchIMMUNOLOGY were delighted to speak with Prof. Xenofon Baraliakos (Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany) around the aims of the BE MOBILE 1 study and the safety and efficacy findings. The abstract ‘Bimekizumab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!